Description: Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Home Page: www.daewoong.com
12, Bongeunsa-ro 114-gil
Seoul,
135-715
South Korea
Phone:
82 2 550 8209
Officers
| Name | Title |
|---|---|
| Mr. Seng-Ho Jeon | Pres, CEO & Director |
| Mr. Chang-Jae Lee | CEO & Exec. Director |
| Jong-Won Seo | Managing Director |
| Hye-Sook Jeon | Sr. Managing Director |
| Won-Geun Lee | Sr. Managing Director |
| Yong-Gu Lee | Managing Director |
| Byung-Woo Kim | Managing Director |
| Jin-Hwan Park | Managing Director |
| Dr. Bongyong Lee | Sr. Managing Director |
| Mr. Jaesik Kim | Sr. Managing Director |
Exchange: KO
Country: KR
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7781 |
| Price-to-Sales TTM: | 1.3756 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1628 |